Over two million people globally may be affected with Crohn's disease.1 Approximately 72% of Crohn’s disease patients have small bowel involvement.2
The PillCam™ Crohn’s system is the only solution that allows physicians to directly and non-invasively visualize the small bowel and colon in a single procedure. Studies have shown that over 60% of Crohn’s disease patients had their treatment changed after a capsule endoscopy procedure.3,4
The PillCam™ SB 3 system allows for direct visualization and monitoring of lesions in the small bowel not detected by upper and lower endoscopy, which may lead to early diagnosis of Crohn’s disease and may expedite therapy.2
Kaplan G. The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology. 2015;12:720-727.
Dubcenco E, Jeejeebhoy K, Petroniene R, Tang S, Zalev A, Gardiner G, Baker J. Capsule endoscopy findings in patients with established and suspected small-bowel Crohn’s disease. Gastrointestinal Endoscopy. 2005;62(4):538-544
Long MD, Barnes E, Isaacs K, Morgan D, Herfarth HH. Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experience. Inflamm Bowel Dis 2011 Sep;17(9):1855-62.
Min SB, Le-Carlson M, Singh N, Nylund CM, Gebbia J, Haas K, et al. Video capsule endoscopy impacts decision making in pediatric IBD: A single tertiary care center experience. Inflamm Bowel Dis. 2013 Sept;19.
Images do not represent all components of the system.